Maintenance therapy in follicular lymphoma
Authors:
- Anne-Sophie MichalletAMAnne-Sophie Michallet
- Bertrand CoiffierBCBertrand Coiffier
- Gilles SallesGSGilles Salles
- 1 September 2011
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Oncology
- Vol. 23 (5) , 449-454
Abstract
This article reviews the potential benefit of maintenance therapy for patients with follicular lymphoma. Follicular lymphoma, despite substantial improvements in survival, is usually incurable. Several randomized studies have shown that the combination of anti-CD20 and chemotherapy can improve overall survival for these patients. Recently, the old concept of maintenance treatment developed for acute leukemias was reintroduced in the treatment of indolent lymphomas. On the basis of its favorable toxicity profile, single agent rituximab remains a valuable option when given in a prolonged schedule to obtain durable remissions. A first remission is easily obtained but relapses appear unavoidable. Patients achieving a partial response have poorer outcomes compared with those achieving complete remission. Furthermore, it has been demonstrated that among patients with follicular lymphoma who reach complete remission, those obtaining negative minimal residual disease, as assessed by molecular biology, have a better outcome compared with those remaining with residual disease. There is, therefore, a rationale to give additional treatment in an attempt to eradicate or to control the lymphoma cells responsible for relapse. An ideal maintenance regimen would have limited toxicity and should be easy to administer. Results of the International Primary Rituximab and Maintenance study show that 2 years of rituximab maintenance prolongs progression free survival, delays the time to next antilymphoma treatment and improves the quality of response in patients with previously untreated follicular lymphoma. Rituximab maintenance was well tolerated with a limited number of adverse events.Keywords
This publication has 20 references indexed in Scilit:
- Long-Term Follow-Up of Patients With Follicular Lymphoma Receiving Single-Agent Rituximab at Two Different Schedules in Trial SAKK 35/98Journal of Clinical Oncology, 2010
- Long-Term Follow-Up of Patients With Newly Diagnosed Follicular Lymphoma in the Prerituximab Era: Effect of Response Quality on Survival—A Study From the Groupe d'Etude des Lymphomes de l'AdulteJournal of Clinical Oncology, 2010
- Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphomaBlood, 2006
- Effect of Single-Agent Rituximab Given at the Standard Schedule or As Prolonged Treatment in Patients With Mantle Cell Lymphoma: A Study of the Swiss Group for Clinical Cancer Research (SAKK)Journal of Clinical Oncology, 2005
- Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 scheduleBlood, 2004
- Single-Agent Rituximab as First-Line and Maintenance Treatment for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Phase II Trial of the Minnie Pearl Cancer Research NetworkJournal of Clinical Oncology, 2003
- Rituximab as First-Line and Maintenance Therapy for Patients With Indolent Non-Hodgkin’s LymphomaJournal of Clinical Oncology, 2002
- Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial.Journal of Clinical Oncology, 1998
- Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group.Journal of Clinical Oncology, 1998
- Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphomaBlood, 1993